Inventor · disambiguated record
Aprile L. Pilon-Clayton
Also filed as: PILON-CLAYTON APRILE L
5 granted patents·5 pending applications·2 citations·filing 2016–2024
68Inventor score
Files withAPC RES ASSETS LLC5THERABRON THERAPEUTICS INC3APCBIO INNOVATIONS INC1PILON CLAYTON APRILE L1
Top patents by PatentIndex Score
10 records- 0175US10676513B2Modification and compositions of human secretoglobin proteinsAPCBIO INNOVATIONS INC·Filed 2019·Granted Jun 9, 2020·1 cites·6 claims
- 0275US10294285B2Modification and compositions of human secretoglobin proteinsTHERABRON THERAPEUTICS INC·Filed 2016·Granted May 21, 2019·1 cites·18 claims
- 0375US2024376162A1Compositions and Methods of Use for Recombinant Human SecretoglobinsAPC RES ASSETS LLC·Filed 2022·Application pending·0 cites
- 0472US2025353886A1Modification and Compositions of Human Secretoglobin ProteinsAPC RES ASSETS LLC·Filed 2024·Application pending·0 cites
- 0565US12162914B2Modification and compositions of human secretoglobin proteinsAPC RES ASSETS LLC·Filed 2021·Granted Dec 10, 2024·0 cites·7 claims
- 0661US2020325190A1Modification and Compositions of Human Secretoglobin ProteinsPILON CLAYTON APRILE L·Filed 2020·Application pending·0 cites
- 0754US11690893B2Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteinsAPC RES ASSETS LLC·Filed 2019·Granted Jul 4, 2023·0 cites·3 claims
- 0848US9844580B2Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitisTHERABRON THERAPEUTICS INC·Filed 2016·Granted Dec 19, 2017·0 cites·45 claims
- 0947US2023241163A1Recombinant Human CC10 Protein for Treatment of Influenza, Ebola and CoronavirusAPC RES ASSETS LLC·Filed 2021·Application pending·0 cites
- 1046US2018125931A1Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitisTHERABRON THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Aprile L. Pilon-Clayton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →